{
    "clinical_study": {
        "@rank": "80529", 
        "acronym": "LOMBARD", 
        "arm_group": [
            {
                "arm_group_label": "25 RRMS patients", 
                "description": "No study treatments administered"
            }, 
            {
                "arm_group_label": "25 PPMS patients", 
                "description": "No study treatments administered"
            }, 
            {
                "arm_group_label": "25 SPMS patients", 
                "description": "No study treatments administered"
            }, 
            {
                "arm_group_label": "25 CIS patients", 
                "description": "No study treatments administered"
            }
        ], 
        "biospec_descr": {
            "textblock": "Plasma, serum and PBMC"
        }, 
        "biospec_retention": "Samples Without DNA", 
        "brief_summary": {
            "textblock": "This study intends to explore evolution of MSRV expression by analyzing the levels of MSRV\n      transcripts in blood, as well as the levels of the MSRV-Env protein in serum of MS patients.\n      The study will be conducted over one year in four cohorts of patients with different forms\n      of MS (remitting-relapsing MS i.e. RRMS, primary-progressive MS i.e. PPMS and\n      secondary-progressive MS i.e. SPMS) and in clinically isolated syndrome (CIS) patients who\n      have suffered a single clinical event but do not comply with diagnosis criteria for definite\n      MS. The MSRV RNA and MSRV-Env protein levels will be correlated with the clinical evolution\n      of patients and with the reverse transcriptase activity, inflammatory markers assessed by\n      cytokines levels. A control group of healthy subjects will be included (the study, GN-E-003,\n      is performed in parallel and is part of another dedicated protocol)."
        }, 
        "brief_title": "Longitudinal Therapeutically Non-interventional Study of MSRV-Env Burden in Patients With Multiple Sclerosis Disease", 
        "completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Multiple Sclerosis (MS)", 
            "Relapsing-Remitting MS", 
            "Primary Progressive MS", 
            "Secondary Progressive MS", 
            "Clinically Isolated Syndrome (CIS)"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Multiple Sclerosis", 
                "Sclerosis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Signature of an informed consent;\n\n          -  Male or female between 18 and 60 years of age;\n\n          -  Patients with PPMS (Revised McDonald criteria 2010) or patients with SPMS or CIS or\n             patients with RRMS (Revised McDonald criteria 2010) ideally without IFN beta therapy\n             at the T0 visit for RRMS patient only.\n\n        Exclusion Criteria:\n\n          -  Positive serology for hepatitis B or C or HIV;\n\n          -  Acute infection at inclusion;\n\n          -  Severe psychiatric disorder;\n\n          -  Autoimmune disease other than MS;\n\n          -  Pregnancy or breastfeeding;\n\n          -  Heavy smokers i.e. more than 10 cigarettes per day;\n\n          -  History of alcohol or drug abuse in the last 3 years;\n\n          -  Participation in a clinical trial (within the last 3 months)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients coming to the Hospital for regular visits."
            }
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01804647", 
            "org_study_id": "GN-E-002"
        }, 
        "intervention": {
            "arm_group_label": [
                "25 RRMS patients", 
                "25 PPMS patients", 
                "25 SPMS patients", 
                "25 CIS patients"
            ], 
            "intervention_name": "No study treatments administered - blood draws only", 
            "intervention_type": "Other"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Multiple sclerosis (MS)", 
            "Relapsing-Remitting MS", 
            "Primary progressive MS", 
            "Secondary progressive MS", 
            "Clinically Isolated Syndrome (CIS)", 
            "Multiple Sclerosis associated RetroVirus (MSRV)", 
            "MSRV envelop protein (MSRV-Env)"
        ], 
        "lastchanged_date": "March 28, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Bron cedex", 
                        "country": "France", 
                        "zip": "69677"
                    }, 
                    "name": "Hospices civils de Lyon - Service de Neurologie A - 59 Boulevard Pinel"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Marseille Cedex 5", 
                        "country": "France", 
                        "zip": "13385"
                    }, 
                    "name": "CHU Timone - Service de Neurologie et CRMBM CNRS 7339 - 264, rue Saint Pierre"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain", 
                        "state": "Cataluna", 
                        "zip": "08035"
                    }, 
                    "name": "Hospital Universitari and Research Institute Vall d'Hebron - Servicio de Neuroimunologia de Nuestro Centro - Pg. Vall d'Hebron 119-129"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lausanne", 
                        "country": "Switzerland", 
                        "zip": "CH-1011"
                    }, 
                    "name": "Centre Hospitalier Universitaire Vaudois - Dpt of Clinical Neurosciences - Neurology /Batiment 10-131 - Rue du Bugnon 46 -"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "France", 
                "Spain", 
                "Switzerland"
            ]
        }, 
        "number_of_groups": "4", 
        "official_title": "A One Year Longitudinal Therapeutically Non-Interventional Study of MSRV-Env Burden in Multiple Sclerosis Patients (RRMS - SPMS - PPMS - CIS) as Assessed by PCR and ELISA in Blood", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "France Competent Authority: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament (ANSM)", 
                "France Ethics Committee: Comit\u00e9 de Protection des Personnes Sud M\u00e9diterran\u00e9e I (CPP)", 
                "Switzerland Ethics Committee only: Commission d'Ethique de la Recherche Clinique Lausanne", 
                "Spain Competent Authority: Agencia E. de Medicamentos y Productos Sanitarios (AEMPS)", 
                "Cataluna Competent Authority: Subdireccion General de Farmacia: Productos Sanitarios", 
                "Spain Ethics Committee: COMIT\u00c9 \u00c9TICO DE INVESTIGACI\u00d3N CL\u00cdNICA Y COMISI\u00d3N DE PROYECTOS DE INVESTIGACI\u00d3N DEL HOSPITAL UNIVERSITARI VALL D'HEBRON (CREC VHIR)"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Monitor the levels of MSRV-Env expression in MS patients (according to McDonald criteria) of different diagnostic subgroups (RRMS, SPMS, PPMS, CIS) over time using 3 approaches:\nMSRV transcripts in PBMC;\nMSRV transcripts in plasma;\nMSRV-Env protein in serum.", 
            "measure": "Monitor the levels of MSRV-Env expression in MS patients (according to McDonald criteria) of different diagnostic subgroups (RRMS, SPMS, PPMS, CIS)", 
            "safety_issue": "No", 
            "time_frame": "1 year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01804647"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Associate the levels of MSRV-Env protein and transcripts", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "measure": "Associate the levels of MSRV-Env as assessed with the 3 approaches with MS relapses/exacerbations and/or clinical evolution (EDSS score) and /or treatment", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "measure": "Associate the levels of MSRV-Env as assessed with the 3 approaches with levels of inflammatory markers and reverse transcriptase activity", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "measure": "Compare levels of MSRV-Env of MS patients to those obtained in a parallel study in Healthy Controls", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }
        ], 
        "source": "GeNeuro Innovation SAS", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "GeNeuro Innovation SAS", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "March 2014"
    }
}